Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

被引：0
|
作者：
Hong, David S.
Strickler, John H.
Fakih, Marwan
Falchook, Gerald Steven
Li, Bob T.
Durm, Greg Andrew
Burns, Timothy F.
Ramalingam, Suresh S.
Goldberg, Sarah B.
Frank, Richard C.
Marrone, Kristen
Shu, Catherine A.
Gandara, David R.
Soman, Neelesh
Henary, Haby Adel
Govindan, Ramaswamy
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] City Hope Comprehens Med Ctr, Duarte, CA USA
[4] Sarah Cannon Res Inst, Denver, CO USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Yale Sch Med, New Haven, CT USA
[10] Nuvance Hlth, Norwalk, CT USA
[11] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Columbia Univ, Med Ctr, New York, NY USA
[13] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[14] Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA
[15] Amgen Inc, Thousand Oaks, CA 91320 USA
[16] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS2669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2669
引用
收藏
页数：4
相关论文
共 50 条
  • [41] ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Gandhi, Leena
    Johnson, Melissa L.
    Opyrchal, Mateusz
    Ramalingam, Suresh
    Janne, Pasi
    Chachoua, Abraham
    Ordentlich, Peter
    Brouwer, Susan
    Sankoh, Serap
    Schmidt, Emmett
    Meyers, Michael L.
    Hellmann, Matthew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [42] KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation
    Riely, G. J.
    Ou, S-H. I.
    Rybkin, I.
    Spira, A.
    Papadopoulos, K.
    Sabari, J. K.
    Johnson, M.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Velastegui, K.
    Cilliers, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S751 - S752
  • [43] Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study
    Besse, B.
    Garrido, P.
    Bennouna, J.
    Mezquita, L.
    Gazzah, A.
    Remon, J.
    Planchard, D.
    Olmedo Garcia, M. E.
    Raimbourg, J.
    Chao, G. Y.
    Gil, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC)
    Concannon, Kyle
    Selvaggi, Giovanni
    Zhou, Joey
    Elamin, Yasir Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
    Christian Kollmannsberger
    Herbert Hurwitz
    Lyudmila Bazhenova
    Byoung Chul Cho
    David Hong
    Keunchil Park
    Karen L. Reckamp
    Sunil Sharma
    Hirak Der-Torossian
    James G. Christensen
    Demiana Faltaos
    Diane Potvin
    Vanessa Tassell
    Richard Chao
    Geoffrey I. Shapiro
    Targeted Oncology, 2023, 18 : 105 - 118
  • [46] Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
    Kollmannsberger, Christian
    Hurwitz, Herbert
    Bazhenova, Lyudmila
    Cho, Byoung Chul
    Hong, David
    Park, Keunchil
    Reckamp, Karen L.
    Sharma, Sunil
    Der-Torossian, Hirak
    Christensen, James G.
    Faltaos, Demiana
    Potvin, Diane
    Tassell, Vanessa
    Chao, Richard
    Shapiro, Geoffrey, I
    TARGETED ONCOLOGY, 2023, 18 (01) : 105 - 118
  • [47] Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
    Zhou, Q.
    Meng, X.
    Sun, L.
    Huang, D.
    Yang, N.
    Yu, Y.
    Zhao, M.
    Zhuang, W.
    Hu, Y.
    Pan, Y.
    Sun, M.
    Shan, J.
    Guo, R-H.
    Chu, Q.
    Xu, C.
    Lin, J.
    Huang, J.
    Huang, M.
    Shen, Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1662
  • [48] Phase 1b/2 study of surufatinib in combination with docetaxel as second-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer (NSCLC)
    Jiang, Wei
    He, Jianbo
    Ning, Ruiling
    Zhao, Yun
    Zhou, Shaozhang
    Wang, Huilin
    Chen, Shubin
    Gan, Haijie
    Lin, Jieqing
    Yu, Qitao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
    Padda, Sukhmani K.
    Rosenberg-Hasson, Yael
    Neal, Joel W.
    Gettinger, Scott N.
    Engelman, Jeffrey A.
    Jaenne, Pasi A.
    West, Howard L.
    Subramaniam, Deepa
    Leach, Joseph W.
    Lara, Primo N.
    Wax, Michael B.
    Wakelee, Heather A.
    Clary, Douglas O.
    Zhou, Lisa
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1072 - S1073
  • [50] A phase 1B study of SNX-5422 plus carboplatin (C) and paclitaxel (P) in patients with advanced non-small-cell lung cancer (NSCLC)
    Gutierrez, Martin
    Giaccone, Giuseppe
    Liu, Stephen V.
    Hao, Zhonglin
    Hilton, Christie
    Hinson, James M.
    Orlemans, Everardus Otto
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345